fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2010-06-15 Basilea Pharmaceutical (Switzerland)

Almirall (Spain)
Toctino® (alitretinoin)
/ severe chronic hand eczema
commercialization/ distribution
See details
2010-06-14 ExonHit Therapeutics (France)
Genmab (Denmark)

splice variant developed using SpliceArray® technology / breast cancer R&D
licensing
See details
2010-06-10 Protagen (Germany)
Bayer Schering Pharma (Germany)
novel biomarkers / endometriosis R&D
other
See details
2010-06-08 Vivalis (France)
Sanofi Pasteur (France)
human monoclonal antibodies / undisclosed infectious diseases R&D
licensing
development
other
See details
2010-06-08 Cellectis bioresearch (France)
Lonza (Switzerland)
  commercialization/ distribution
development
See details
2010-06-08 Zealand Pharma (Denmark)
Sanofi Aventis (France)
lixisenatide (GLP-1 (glucagon-like-peptide-1) receptor agonist) / type 2 diabetes
R&D
commercialization/ distribution
development
See details
2010-06-07 Lonza (Switzerland)
California Stem Cell (USA)
  licensing
other
See details
2010-06-04 Ascenta Therapeutics (USA)
Sanofi-Aventis (France)
orally-active, small-molecule drug candidates inhibiting the interaction between HDM2 (Human Double Minute 2) and p53. / cancer R&D
licensing
manufacturing
commercialization/ distribution
development
See details
2010-06-01 Orexo (Sweden)
Ortho-McNeil-Janssen Pharmaceuticals (USA)
Janssen Pharmaceutica (Belgium)
OX-CLI and OX-ESI programs from Orexo and a third internal program from Ortho-McNeil-Janssen Pharmaceuticals. This latest program is focusing on discovering and developing innovative small-molecules against an undisclosed target. / asthma, chronic obstructive pulmonary disease, and other inflammatory diseases. R&D
licensing
commercialization/ distribution
development
marketing/ promotion
See details
2010-05-26 CEVEC Pharmaceuticals (Germany)
Pevion Biotech (Switzerland)
CAP-T™ cell expression technology
The technology is based on CAP® cells, a human immortalized cell line for stable protein production derived from amniocytes and developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression levels even for difficult to express proteins. They have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns. / infectious diseases
licensing
other
See details
2010-05-26 Massachusetts Institute of Technology Center for Biomedical Innovation (USA)
Sanofi-Aventis (France)
  R&D
See details
2010-05-25 Aureus Pharma (France)
Ariadne (USA)
  R&D
commercialization/ distribution
other
See details
2010-05-18 TcLand Expression (France)
Hospices Civils de Lyon (France)
novel biomarkers / rheumatoid arthritis R&D
See details
2010-05-17 ElexoPharm (Germany)
Merck & Co (USA)
novel candidates targeting aldosterone synthase / cardiovascular disease R&D
licensing
commercialization/ distribution
development
See details
2010-05-12 Biotage (Sweden)
University of Copenhagen (Denmark)
peptide synthesis and protein chemistry R&D
See details
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [65]